Current Status
Not Enrolled
Price
Closed
Get Started
This course is currently closed
Course
References

Orchestrating Care of Cancer Pain in GP Practice

Thank you for choosing to update your knowledge on the central role of GP’s in assessing and managing patients with cancer pain. Despite progress in cancer treatments, cancer pain remains underestimated, poorly assessed, and undertreated, particularly in the most severe cases. This online CPD activity will assist GPs take the clinical lead in the assessment and management of cancer pain.

This activity will take approximately 30 minutes to complete and can be completed at your own pace over a number of sessions.

Learning outcomes

  • Identify patient barriers to the management of cancer pain

  • Address patient/carer barriers to opioid use in cancer pain

  • Develop and implement a multimodal pain management plan

  • Take the clinical lead in coordinating multidisciplinary cancer pain management

Time to complete: 30 minutes

CPD Points

RACGP CPD activity: 1 CPD activity point

RACGP CPD 1 point logo

Disclaimer

Opioids are only to be used after other modalities have failed or are not appropriate, and only in carefully selected patients.

Opioids should only be prescribed as a component of comprehensive multidisciplinary and multimodal pain management.

When considering an opioid for your patients with chronic severe pain, it is important to consider the side effects and potential risks, as well as the benefits of treatment.

Education Provider

RACGP CPD-Social-1200x628-1

 

 

Scius Healthcare Solutions Pty Ltd
PO Box 84 Northbridge NSW 1560
P +61 2 9958 1481
www.scius.com.au
SCIUS1865A AU-TARG-2000001 Dec 2020

1. Bennett MI, Eisenberg E, Ahmedzai SH, Bhaskar A, O'Brien T, Mercadante S, et al. Standards for the management of cancer-related pain across Europe-a position paper from the EFIC task force on cancer pain. Eur J Pain. 2019;23:660-668

2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Adult cancer pain, verion 1 2020. 2020

3. Lovell M, Boyle F. Cancer pain management. Medicine Today 2010;11:33-38

4. George B, Minello C, Allano G, Maindet C, Burnod A, Lemaire A. Opioids in cancer-related pain: Current situation and outlook. Support Care Cancer. 2019;27:3105-3118

5. van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on prevalence of pain in patients with cancer: Systematic review and meta-analysis. J Pain Symptom Manage. 2016;51:1070-1090 e1079

6. Palliative Care Expert Group. Therapeutic Guidelines Palliative Care, Therapeutic Guidelines Complete, March 2020 online edition.: Therapeutic Guidelines Limited; 2016.

7. Mehta A CL. Understanding of the concept of ‘‘total pain’’. Journal of Hospice and Palliative Nursing. 2008;10:26-32

8. Portenoy RK DL. Overview of cancer pain syndromes. UpToDate. 2019

9. Dalal S, Bruera E. Pain management for patients with advanced cancer in the opioid epidemic era. Am Soc Clin Oncol Educ Book. 2019;39:24-35

10. Clark K. Care at the very end-of-life: Dying cancer patients and their chosen family's needs. Cancers (Basel). 2017;9

11. Glare P, Ikemoto T. Managing pain in cancer survivors. Pain Management Today. 2018;5:17-22

12. Gunnarsdottir S, Sigurdardottir V, Kloke M, Radbruch L, Sabatowski R, Kaasa S, et al. A multicenter study of attitudinal barriers to cancer pain management. Support Care Cancer. 2017;25:3595-3602

13. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: A rational approach to the treatment of chronic pain. Pain Med. 2005;6:107-112

14. Katelaris P, Krassas G. The clinical challenge of opioid-induced constipation: Insights from the opioid-induced constipation clinical audit. J Gen Prac. 2016;4:1-5

15. Analgesic Expert Group. Therapeutic Guidelines Analgesic, Therapeutic Guidelines Complete, March 2020 online edition.: Therapeutic Guidelines Limited; 2012.

16. Schug S, Pogatzki-Zhan E. Chronic pain after surgery or injury. Pain Clinical Updates. 2011;XIX(1):1-5

17. Therapeutic Goods Administration. Prescription opioids: Information for consumers, patients and carers. 2020 [accessed 28 December 2020]. Available from: https://www.tga.gov.au/prescription-opioids-information-consumers-patients-and-carers

18. White A. Safe and effective use of opioids in patients with advanced cancer. Pain Management Today. 2016;3:24-28

19. Australian Medicines Handbook online. Available from: https://amhonline.amh.net.au.

20. Targin modified release tablets product information. 2020

21. Faculty of Pain Medicine, Australian and New Zealand College of Anaesthetists. Opioid dose equivalence. 2019

22. Paice JA. Navigating cancer pain management in the midst of the opioid epidemic. Oncology (Williston Park). 2018;32:386-390, 403

23. Gaertner J, Boehlke C, Simone CB, 2nd, Hui D. Early palliative care and the opioid crisis: Ten pragmatic steps towards a more rational use of opioids. Ann Palliat Med. 2019;8:490-497

24. Ward J, Vogelzang N, Davis B. Initial management of regionally localized intermediate-, high-, and very high-risk prostate cancer. UpToDate. 2020

25. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the opioid risk tool. Pain Med. 2005;6:432-442

26. Morris L, Gorayski P, Turner S. Back pain in a cancer patient: A case study. Aust Fam Physician. 2014;43:529-530

27. Chan BK, Tam LK, Wat CY, Chung YF, Tsui SL, Cheung CW. Opioids in chronic non-cancer pain. Expert Opin Pharmacother. 2011;12:705-720

28. Kahan M, Mailis-Gagnon A, Wilson L, Srivastava A, National Opioid Use Guideline G. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: Clinical summary for family physicians. Part 1: General population. Can Fam Physician. 2011;57:1257-1266, e1407-1218

29. Sartor A, DiBiase S. Bone metastases in advanced prostate cancer: Clinical manifestations and diagnosis. . UpToDate. 2020

30. Ahmedzai SH, Leppert W, Janecki M, Pakosz A, Lomax M, Duerr H, et al. Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain. Support Care Cancer. 2015;23:823-830

31. Ahmedzai SH, Nauck F, Bar-Sela G, Bosse B, Leyendecker P, Hopp M. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med. 2012;26:50-60

32. Sze W, Shelley M, Held I, Mason M. Palliation of metastatic bone pain: Single fraction versus multifraction radiotherapy. Cochrane Database of Systematic Reviews 2002